Thrombocythemia, Essential research hub
7 indexed studies · 4 currently recruiting
- recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
United States · Australia · Hong Kong - ongoing, recruitingTherapeutic use (Phase IV)
HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
This study looks at how well a medicine called hydroxycarbamide works for people with a blood condition called polycythaemia vera. It aims to identify patients who might not respond well to this treatment from the beginning, helping doctors choose the best care.
Germany - recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
This study looks at how conditions like Polycythemia Vera and Thrombocythemia change over time. It compares people who had one condition and then developed another, to help doctors understand the diseases better and improve care for patients.
United States · Germany · Italy - active not recruitingPHASE3
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
This study is testing a new medicine called rusfertide for people with polycythemia vera (PV). It aims to see if rusfertide can help control symptoms and blood thickness better than current treatments, reducing the need for frequent blood draws.
United States · Australia · Austria - recruitingPHASE3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Stein AG, Stein – Switzerland, in healthy adult, human subjects under fasting condition.
This study compares a new 20mg ruxolitinib tablet from Sun Pharma with the existing Jakavi 20mg tablet. It's for healthy adults to see if the new tablet works the same way in the body when taken on an empty stomach. This helps ensure new medicines are just as effective.
Romania - recruitingPHASE3
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
This study compares two treatments, givinostat and hydroxyurea, for polycythemia vera (PV). It aims to see how well they work and if they are safe for patients with a high risk of blood clots. It focuses on PV caused by a specific gene change (JAK2V617F).
United States · Austria · Bulgaria